BC179 Relieves Discomfort After Drinking

NCT ID: NCT06899620

Last Updated: 2025-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-01

Study Completion Date

2025-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the effectiveness and safety of probiotic strain BC179 in reducing alcohol absorption in the gut, thereby lowering health risks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drinking Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic group

10B CFU/Sachet/Day BC179 ; Storage: Store in cool and dry place without sun exposure

Group Type EXPERIMENTAL

Probiotic group

Intervention Type DIETARY_SUPPLEMENT

The experimental phase of this study lasted for 60 days.

Placebo group

Dextrin one Sachet/Day; Storage: Store in cool and dry place without sun exposure

Group Type PLACEBO_COMPARATOR

Placebo group

Intervention Type DIETARY_SUPPLEMENT

The experimental phase of this study lasted for 60 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic group

The experimental phase of this study lasted for 60 days.

Intervention Type DIETARY_SUPPLEMENT

Placebo group

The experimental phase of this study lasted for 60 days.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants must be aged between 18 and 65 years.
2. They should have a documented history of long-term alcohol consumption, defined as consuming at least 20 grams of ethanol per day for at least one year. This is calculated using the formula: volume (mL) × alcohol content (%) × 0.8.
3. They must provide written informed consent and be willing to comply with the study procedures.

Exclusion Criteria

1. History of chronic liver, gastrointestinal, or systemic metabolic disorders.
2. Use of products with similar functions to the investigational formulation within the past two weeks.
3. Use of antibiotics, laxatives, or dietary supplements within the past four weeks.
4. Documented history of hypertension or diabetes.
5. Severe allergies or immune deficiencies.
6. Pregnancy, lactation, or planning pregnancy without effective contraception during the study period.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wecare Probiotics Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wu Ying

Luoyang, Henan, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WK20250323

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.